Phase II, Open-Label Study to Evaluate Safety and Explore Efficacy of Escalating Doses of Bevacizumab-IRDye800CW as an Optical Imaging Agent to Detect Cancer Tissue Delineation During Tumor Resection Surgery in Patients with Breast Cancer

Category Primary study
Registry of TrialsEU Clinical Trials Register
Year 2015
This article has no abstract
Epistemonikos ID: b9555b4313bb64c13e178605872600a7b25c6b08
First added on: Jan 22, 2025